Insider · CIK 0002034668
Ivan Hyep
Files at BCAX (Bicara Therapeutics Inc.). First filing Oct 8, 2025, latest May 26, 2026.
Ivan Hyep files SEC Form 4 as CFO at BCAX (Bicara Therapeutics Inc.). Since Oct 8, 2025, Ivan Hyep has reported 0 open-market buys worth $0 and 9 open-market sells worth $2.1M, the latest filed on May 26, 2026.
A track record needs three past buys with six months of prices behind them; Ivan Hyep has 0, so none is measured yet.
The newest scored trade: sold $188k of BCAX on May 21, 2026, filed May 26, 2026, scored 14 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 7 sells worth $1.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BCAX: Bicara Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | Bicara Therapeutics Inc. | $188k 9,200 shares | -6% | +139% from low-13% from high | |
| 14Weak | Bicara Therapeutics Inc. | $212k 9,200 shares | -6% | +165% from low-4% from high | |
| 13Weak | Bicara Therapeutics Inc. | $170k 9,200 shares | -6% | +111% from low-8% from high | |
| 21Weak | Bicara Therapeutics Inc. | $301k 16,518 shares | -10% | +106% from low-6% from high | |
| 1Weak | Bicara Therapeutics Inc. | $34k 1,882 shares | -1% | +102% from low-8% from high | |
| 6Weak | Bicara Therapeutics Inc. | $168k 9,200 shares | -6% | +110% from low-4% from high | |
| 22Weak | Bicara Therapeutics Inc. | $341k 18,400 shares | -13% | +107% from low-15% from high | |
| 12Weak | Bicara Therapeutics Inc. | $117k 6,415 shares | -4% | +110% from low-28% from high | |
| 26Weak | Bicara Therapeutics Inc. | $553k 30,385 shares | -20% | +107% from low-28% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 22, 2025 | BCAX Bicara Therapeutics Inc. | 9,200 0.02% of outstanding | $164k | Dec 22, 2025 | $1.0M |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | 17,795 0.03% of outstanding | $330k | Nov 24, 2025 | $681k |
| Nov 21, 2025 | BCAX Bicara Therapeutics Inc. | 605 0.00% of outstanding | $11k | Nov 21, 2025 | $670k |
| Oct 9, 2025 | BCAX Bicara Therapeutics Inc. | 6,415 0.01% of outstanding | $115k | Oct 9, 2025 | $553k |
| Oct 8, 2025 | BCAX Bicara Therapeutics Inc. | 5,627 0.01% of outstanding | $102k | Oct 8, 2025 | $451k |
| Oct 7, 2025 | BCAX Bicara Therapeutics Inc. | 18,244 0.03% of outstanding | $328k | Oct 7, 2025 | $118k |
| Oct 6, 2025 | BCAX Bicara Therapeutics Inc. | 6,514 0.01% of outstanding | $111k | Oct 6, 2025 | none |
Transactions
Every row this insider has filed, 42 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +9,200 | $3.79 | $35k | 154,555 | May 26, 2026 |
| May 21, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -9,200 | $20.42 | $188k | 145,355 | May 26, 2026 |
| May 21, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,200 | $0.00 | $0 | 70,584 | May 26, 2026 |
| Apr 21, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +9,200 | $3.79 | $35k | 154,555 | Apr 22, 2026 |
| Apr 21, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -9,200 | $23.00 | $212k | 145,355 | Apr 22, 2026 |
| Apr 21, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,200 | $0.00 | $0 | 39,744 | Apr 22, 2026 |
| Mar 23, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +9,200 | $3.79 | $35k | 154,555 | Mar 24, 2026 |
| Mar 23, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -9,200 | $18.52 | $170k | 145,355 | Mar 24, 2026 |
| Mar 23, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,200 | $0.00 | $0 | 48,944 | Mar 24, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +7,318 | $3.79 | $28k | 152,673 | Mar 5, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +6,237 | $3.79 | $24k | 158,910 | Mar 5, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -13,555 | $18.22 | $247k | 145,355 | Mar 5, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +2,963 | $3.79 | $11k | 148,318 | Mar 5, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -2,963 | $18.25 | $54k | 145,355 | Mar 5, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,318 | $0.00 | $0 | 58,144 | Mar 5, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,237 | $0.00 | $0 | 82,747 | Mar 5, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,963 | $0.00 | $0 | 79,784 | Mar 5, 2026 |
| Feb 2, 2026 | BCAX Bicara Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Feb 4, 2026 |
| Jan 22, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +1,882 | $3.79 | $7,132 | 147,237 | Jan 26, 2026 |
| Jan 22, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -1,882 | $18.15 | $34k | 145,355 | Jan 26, 2026 |
| Jan 22, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,882 | $0.00 | $0 | 65,462 | Jan 26, 2026 |
| Dec 22, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +9,200 | $3.79 | $35k | 154,555 | Dec 23, 2025 |
| Dec 22, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -9,200 | $18.31 | $168k | 145,355 | Dec 23, 2025 |
| Dec 22, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,200 | $0.00 | $0 | 88,984 | Dec 23, 2025 |
| Nov 21, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +605 | $3.79 | $2,293 | 145,960 | Nov 25, 2025 |
| Nov 21, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -605 | $18.15 | $11k | 145,355 | Nov 25, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +17,795 | $3.79 | $67k | 163,150 | Nov 25, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -17,795 | $18.55 | $330k | 145,355 | Nov 25, 2025 |
| Nov 21, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -605 | $0.00 | $0 | 115,979 | Nov 25, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,795 | $0.00 | $0 | 98,184 | Nov 25, 2025 |
| Oct 9, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +6,415 | $3.79 | $24k | 151,770 | Oct 10, 2025 |
| Oct 9, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -6,415 | $18.23 | $117k | 145,355 | Oct 10, 2025 |
| Oct 9, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,415 | $0.00 | $0 | 116,584 | Oct 10, 2025 |
| Oct 6, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +6,514 | $3.79 | $25k | 151,869 | Oct 8, 2025 |
| Oct 6, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -6,514 | $18.17 | $118k | 145,355 | Oct 8, 2025 |
| Oct 7, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +18,244 | $3.79 | $69k | 163,599 | Oct 8, 2025 |
| Oct 7, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -18,244 | $18.22 | $332k | 145,355 | Oct 8, 2025 |
| Oct 8, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +5,627 | $3.79 | $21k | 150,982 | Oct 8, 2025 |
| Oct 8, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -5,627 | $18.21 | $102k | 145,355 | Oct 8, 2025 |
| Oct 6, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,514 | $0.00 | $0 | 146,870 | Oct 8, 2025 |
| Oct 7, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,244 | $0.00 | $0 | 128,626 | Oct 8, 2025 |
| Oct 8, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,627 | $0.00 | $0 | 122,999 | Oct 8, 2025 |
Questions about Ivan Hyep
Answered from the filings on this page, as of the latest one.
Is Ivan Hyep buying or selling?
In the last 12 months Ivan Hyep reported 0 open-market buys worth $0 and 7 open-market sells worth $1.4M on SEC Form 4; the latest was sold $188k of BCAX on May 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Ivan Hyep's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ivan Hyep has 0.
Where does Ivan Hyep file Form 4?
Ivan Hyep has filed Form 4 at BCAX (Bicara Therapeutics Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.